Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination ...

Luveltamab tazevibulin (luvelta) + bevacizumab (15 mg/kg) every 3 weeks showed 56% ORR in late-stage ovarian cancer, selected as RP2D. Preliminary antitumor activity (35% ORR) observed across dose ranges. Expansion at RP2D ongoing with 23 additional patients; initial data expected H1 2025. No new safety signals detected.